Maximum Strength Acid Reducer Without prescription: NDMA impurity

Last updated

2022-03-11

Summary

Product

Maximum Strength Acid Reducer Without prescription

Issue

Health products - Product quality

What to do

See instructions below.

Brand	Product Name	Market Authorization	Dosage Form	Strength	Lot
Maximum Strength Acid Reducer Without prescription	Maximum Strength Acid Reducer Without prescription	DIN 02293471	Tablet	Ranitidine (Ranitidine Hydrochloride) 150mg	629744A, 629744B, 629744E, 629973C, 629973D, 632043A, 632043F, 632058B, 632058J, 629744F, 632058H, 629744G, 629973B, 632043D, 632043E, 632058A, 631893C, 629744H, 632058I, 629974A, 629974B, 629744I, 632043G, 632058D, 632058G, 629744J, 632043H, 629973A, 632043B, 629744C

Presence of N-nitrosodimethylamine (NDMA) close or above the acceptable concentration limit in affected lots.

Talk to your doctor or pharmacist at your earliest convenience about alternative, non-ranitidine treatment options appropriate for your health circumstances. There are many prescription and over-the-counter drug alternatives in Canada that are authorized for the same or similar uses as ranitidine.
Individuals taking a prescription ranitidine drug, including a recalled product, should not stop taking it unless they have spoken to their health care provider and obtained alternative treatment, as the risk of not treating the condition may be greater than the risk related to NDMA exposure.
Contact your health care provider if you have taken a ranitidine product and you have concerns about your health.
Report any health product adverse events or complaints to Health Canada.

Previous recalls or alerts

Background

Depth of recall: Retailers

Details

Original published date: 2022-03-11

Alert / recall type

Health product recall